Business Context and Reporting Period
This Form 6-K, dated February 4, 2005, reports the Annual Report to Shareholders for Novartis AG for the fiscal year ended December 31, 2004. Novartis is a global pharmaceutical and consumer health company headquartered in Basel, Switzerland. The reporting period covers the company's ninth business year, characterized by record net sales and net income driven by strong organic growth in both its Pharmaceuticals and Consumer Health divisions.
Key Financial Metrics (2004 vs. 2003)
| Metric (USD Millions) | 2004 | 2003 | Change (%) |
|---|---|---|---|
| Net Sales | 28,247 | 24,864 | +14% |
| Operating Income | 6,539 | 5,889 | +11% |
| Net Income | 5,767 | 5,016 | +15% |
| Return on Sales | 23.1% | 23.7% | -0.6 pp |
| Research & Development | 4,207 | 3,756 | +12% |
| Free Cash Flow | 3,359 | 3,628 | -7% |
| Earnings Per Share (USD) | 2.36 | 2.03 | +16% |
| Dividend per Share (CHF) | 1.05 | 1.00 | +5% |
Note: Net sales growth was 9% in local currencies. Operating income margin declined slightly due to one-time charges in the Sandoz and Medical Nutrition units.
Material Changes and Segment Performance
- Pharmaceuticals Division: Net sales rose 15% (10% in local currencies) to $18.5 billion, outpacing the market. Operating income grew 19% to $5.3 billion, with margins expanding to 28.4%. Growth was driven by cardiovascular (Diovan, Lotrel) and oncology (Gleevec/Glivec, Zometa, Femara) franchises.
- Consumer Health Division: Net sales increased 10% (5% in local currencies) to $9.8 billion. However, operating income declined 11% to $1.2 billion due to one-off charges totaling $120 million, including restructuring costs at Sandoz and a legal provision in Medical Nutrition.
- Sandoz (Generics): Sales grew 5% but operating income fell 50% to $235 million due to intense price competition in the US and Germany and a challenging comparison to a strong 2003 performance.
- Acquisitions: Significant 2004 acquisitions included Sabex Inc. (Canada) for $565 million and the adult medical nutrition business of Mead Johnson for $385 million.
Guidance, Outlook, and Risks
- Pipeline and Innovation: Novartis maintains a robust pipeline with 75 projects in clinical development, 52 of which are in Phase II, III, or registration. Key upcoming milestones include Phase III data for LAF237 (diabetes) and SPP100 (hypertension) in late 2005, and regulatory submissions for PTK787 (oncology).
- Dividend: The Board proposed a 5% dividend increase to CHF 1.05 per share, reflecting strong organic growth.
- Risks and Contingencies:
- Legal Investigations: Novartis is subject to an investigation by the US Department of Justice regarding marketing practices in the US enteral pump market and a UK Serious Fraud Office investigation into Sandoz UK marketing practices.
- Patent Litigation: The company faces significant patent litigation risks, particularly in the generics sector, which could limit product launches or result in damages.
- Regulatory Environment: Increasing pressure on pricing and reimbursement from governments globally poses a risk to future margins.
- Corporate Citizenship: The company contributed $570 million in 2004 to access-to-medicine programs, including free treatments for leprosy, malaria, and tuberculosis.
Key Facts for Investor Verification
- Verify the impact of the US Department of Justice investigation into the enteral pump market on future legal provisions and operating income.
- Monitor the resolution of the UK Serious Fraud Office investigation regarding Sandoz UK.
- Track the progress of key pipeline compounds (LAF237, SPP100, PTK787) and their regulatory approval timelines in 2005.
- Assess the sustainability of Sandoz's operating margins amidst ongoing price competition in the US and European generics markets.
- Confirm the execution of the fourth share repurchase program, which began in August 2004 with a target of approximately $2.4 billion.